NK Cells and γδT Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT)

Moniek A. de Witte, Jürgen Kuball, Jeffrey S. Miller

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Purpose of Review: The outcome of allogeneic stem cell transplantation (allo-HCT) is still compromised by relapse and complications. NK cells and γδT cells, effectors that both function through MHC-unrestricted mechanisms, can target transformed and infected cells without inducing graft-versus-host disease (GVHD). Allo-HCT platforms based on CD34+ selection or αβ-TCR depletion result in low grades of GVHD, early immune reconstitution (IR) of NK and γδT cells and minimal usage of GVHD prophylaxis. In this review we will discuss strategies to retain and expand the quantity, diversity, and functionality of these reconstituting innate cell types. Recent Findings: Bisphosphonates, IL-15 cytokine administration, specific antibodies, checkpoint inhibitors, and (CMV based) vaccination are currently being evaluated to enhance IR. All these approaches have shown to potentially enhance both NK and γδT cell immuno-repertoires. Summary: Rapidly accumulating data linking innate biology to proposed clinical immune interventions will give unique opportunities to unravel shared pathways which determine the graft-versus-tumor effects of NK and γδT cells.

Original languageEnglish (US)
Pages (from-to)301-311
Number of pages11
JournalCurrent Stem Cell Reports
Volume3
Issue number4
DOIs
StatePublished - Dec 1 2017

Bibliographical note

Funding Information:
Acknowledgments Moniek A. de Witte received the following funding: KWF UU 2015-7553. Jeffrey S. Miller received the following funding: NIH/NCI P01 CA65493, NIH/NCI P01 CA111412, NIH/NCI R35 CA197292. Funding for this study was provided by ZonMW 43400003 and VIDI-ZonMW 917.11.337, KWF UU 2010-4669, UU 2013-6426, UU 2014-6790 and UU 2015-7601, Vrienden van het UMCU, AICR 10-0736 & 15-0049 to J.K.

Funding Information:
Moniek A. de Witte received the following funding: KWF UU 2015-7553. Jeffrey S. Miller received the following funding: NIH/NCI P01 CA65493, NIH/NCI P01 CA111412, NIH/NCI R35 CA197292. Funding for this study was provided by ZonMW 43400003 and VIDI-ZonMW 917.11.337, KWF UU 2010-4669, UU 2013-6426, UU 2014-6790 and UU 2015-7601, Vrienden van het UMCU, AICR 10-0736 & 15-0049 to J.K. This article is part of the Topical Collection on Cellular Therapies: Preclinical and Clinical Moniek A. de Witte has no conflict of interest. J?rgen Kuball is scientific co-founder and CSO of Gadeta BV (www.gadeta.nl) and is a shareholder. He is also an inventor on different patents given to Gadeta via the University Medical Centre Utrecht that deal with ?? TCR, processing strategies, and their ligands. In addition, he has received grants from Novartis and Miltenyi Biotech. Jeffrey S. Miller is a consultant and scientific advisory for Fate Therapeutics and GT Biopharma. He also is on the scientific advisory board for Celgene. In addition, he has pending patents via the University of Minnesota for Fate Therapeutics and GT Biopharma.

Publisher Copyright:
© 2017, Springer International Publishing AG.

Keywords

  • Allogeneic stem cell transplantation
  • Immune reconstitution
  • NK cells
  • γδT cells

Fingerprint

Dive into the research topics of 'NK Cells and γδT Cells for Relapse Protection after Allogeneic Hematopoietic Cell Transplantation (HCT)'. Together they form a unique fingerprint.

Cite this